Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
November 09, 2021 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
November 05, 2021 07:05 ET
|
MannKind
A Technosphere® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in...
MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
November 02, 2021 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to...
Progress Update on Tyvaso DPI™ New Drug Application
October 18, 2021 06:00 ET
|
MannKind
Complete response received by United Therapeutics cites an open inspection issue at a third-party analytical testing center; no other deficiencies citedNo issues identified regarding operations...
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population
October 04, 2021 07:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
September 29, 2021 16:24 ET
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference
September 28, 2021 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
Mannkind Corporation Participating at Upcoming Conferences
September 15, 2021 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 06:05 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
MannKind Corporation Reports 2021 Second Quarter Financial Results
August 11, 2021 16:00 ET
|
MannKind
Conference Call to Begin Today at 5:00 PM ET 2Q 2021 Total Revenues of $23.3 million; +54% vs. 2Q 20202Q 2021 Afrezza Net Revenue of $10.0 million; +43% vs. 2Q 2020$201.4 million of Cash, Cash...